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Abstract  
The ATP-binding cassette (ABC) transporters of class G display a different domain 
organisation than P-glycoprotein/ABCB1 and bacterial homologues with a nucleotide-
binding domain preceding the transmembrane domain. The linker region connecting 
these domains is unique and its function and structure cannot be predicted. 
Sequence analysis revealed that the human ABCG2 linker contains a LSGGE 
sequence, homologous to the canonical C-motif/ABC signature present in all ABC 
nucleotide-binding domains. Predictions of disorder and of secondary structures 
indicated that this C2-sequence was highly mobile and located between an -helix 
and a loop similarly to the C-motif. Point mutations of the two first residues of the 
C2-sequence fully abolished the transport-coupled ATPase activity, and led to the 
complete loss of cell resistance to mitoxantrone. The interaction with potent, selective 
and non-competitive, ABCG2 inhibitors was also significantly altered upon mutation. 
These results suggest an important mechanistic role for the C2-sequence of the 
ABCG2 linker region in ATP binding and/or hydrolysis coupled to drug efflux. 
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Introduction 
The ABCG2 transporter was discovered simultaneously in three different groups; it 
was called ABCP for its abundance in placenta [1], BCRP as a breast cancer 
resistance protein [2] and MXR for its induced resistance to mitoxantrone [3]. Its 
overexpression in cancer cells was identified to strongly contribute to multidrug 
resistance, similarly to previously discovered P-glycoprotein/ABCB1 [4, 5] and 
MRP1/ABCC1 [6]. ABCG2 also plays an essential physiological control within 
barriers protecting sensitive organs [7, 8] as well as in stem cells of which it is 
considered to be a marker [9]. 
 All members of the ATP-binding cassette (ABC) superfamily are constituted of 
cytosolic nucleotide-binding domains (NBDs), responsible for ATP binding and 
hydrolysis, and two transmembrane domains (TMDs) generally comprising 6 
-helical spans ensuring substrate transport across the membrane. These four 
domains are fused through linkers into a single TMD1-NBD1-TMD2-NBD2 
polypeptide, as a “full-transporter” in P-glycoprotein (ABCB1) and MRP1 (which also 
contains an additional N-terminal TMD0 domain). In contrast to ABCB1 and MRP1, 
ABCG2 is a “half-transporter”, with a single NBD fused to a single TMD, and 
therefore requires dimerization, at a minimum, to form a functional unit. Its NBD-TMD 
domain arrangement is different; as a consequence, the linker connecting both 
domains is unique and its structure cannot be modeled using a template, such as the 
crystal structures of P-glycoproteins from mice [10] or Caenorhabditis elegans [11], 
or of a bacterial homologue [12].  
 All NBDs of the ABC transporters contain several ATP-binding motifs: in 
addition to the Walker-A and Walker-B motifs also present in other ATPases, a 
conserved specific sequence LSGGQ, followed by three basic residues, is called “C-
motif” or “C-loop” and is considered to be an “ABC signature”. Its critical function in 
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ATP hydrolysis and in coupled substrate transport was demonstrated by site-directed 
mutagenesis in various transporters such as P-glycoprotein [13, 14], MRP1 [15], TAP 
[16, 17] and MalK [18]. The crystal structure of HlyB precisely identified the 
interactions with different moieties (adenine, ribose and -phosphate) of bound ATP, 
and additionally showed protein-protein interactions with the Walker-A motif of the 
other NBD [19]. The C-motif is therefore contributing to NBD dimerization, which is 
required for ATP hydrolysis and its coupling to the transport process by two types of 
direct interactions: (1) with ATP, mainly bound to the other NBD through Walker-A, 
Walker-B and other motifs, and (2) with the Walker-A motif of the other NBD.    
 In the present work, an additional C-motif LSGGE, called the C2-sequence, 
was identified at positions 352-356, within the poorly known linker region of human 
ABCG2. The aim was therefore to look at its conservation among ABCGs and 
species, and a potential function. The results show that the C2-sequence is predicted 
to be quite mobile and structurally similar to the C-motif; point mutations fully altered 
ABCG2-mediated coupled ATPase activity and cellular multidrug resistance, 
suggesting a critical role in coupling between ATP hydrolysis and drug efflux. 
 
Materials and Methods 
Sequence alignment and structure predictions 
Sequences were downloaded from UniProt [20]. Sequence alignments were 
generated using ClustalW using default parameters [21], analyzed and displayed in 
Cinema5 (http://aig.cs.man.ac.uk/research/utopia/cinema/cinema.php). Sequences 
were queried for the ABC signature pattern (ProSite; 
http://prosite.expasy.org/PDOC00185) employing the preg software from EMBOSS 
(The European Molecular Biology Open Software Suite) [22]. Two conceptually 
different algorithms were used to predict disorder tendency with default parameters 
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including DISOPRED2 [23] and IUPRED [24]. Secondary structure prediction was 
done employing also different predictors: Prof (http://www.aber.ac.uk/~phiwww/prof/), 
Jnet [25] and PSI [26]. 
 
Compounds 
Commercial reagents were of the highest available purity grade: mitoxantrone 
(≥97%) and Ko143 (≥98%) were purchased from Sigma-Aldrich (France), and 
nilotinib from Selleck Chemicals (Boston, MA). Chromone 1 was obtained as 
previously described [27]. The 5D3 monoclonal antibody was purchased from 
eBioscience and BXP-21 antibody from Alexis Biochemicals. 
 
Generation of Mutants 
The L352A, S353A, G354A, G355A and E356A point mutants were generated by 
site-directed mutagenesis in a pcDNA3.1 vector (Invitrogen) carrying the full length 
ABCG2 cDNA, kindly provided by the laboratory of Dr. Douglas Ross. Sited-directed 
mutagenesis was carried out using the "QuickChange® Site-Directed Mutagenesis" 
kit (Stratagene). The plasmid containing ABCG2 was amplified by PCR from primers 
containing the desired mutation. The full-length sequences of all mutant constructs 
were tested for correctness by sequencing. The designed primer sequences are 
presented in the following table, where the mutated nucleotides are in bold letters. 
Primers Sequences 
L352A-Fw ACAAAAGCTGAATTACATCAAGCTTCCGGGGGTGAGAAG 
 
L352A-Rv CTTCTCACCCCCGGAAGCTTGATGTAATTCAGCTTTTGT 
S353A-Fw AAAGCTGAATTACATCAACTTGCCGGGGGTGAGAAGAAG 
 
S353A-Rv CTTCTTCTCACCCCCGGCAAGTTGATGTAATTCAGCTTT 
G354A-Fw CCTGAATTACATCAACTTTCCGCGGGTGAGAAGAAGAAG  
 
G354A-Rv CTTCTTCTTCTCACCCGCGGAAAGTTGATGTAATTCAGG  
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G355A-Fw TTACATCAACTTTCCGGGGCTGAGAAGAAGAAGAAGATC 
G355A-Rv GATCTTCTTCTTCTTCTCAGCCCCGGAAAGTTGATGTAA  
 
E356A-Fw TTACATCAACTTTCCGGGGGTGCGAAGAAGAAGAAGATC  
 
E356A-Rv GATCTTCTTCTTCTTCGCACCCCCGGAAAGTTGATGTAA  
 
Cell cultures 
Human Embryonic 293 cell line (CelluloNet n°109) was transfected (Nucleofector 
technique, solution 5, programme A23, LONZA) with either ABCG2 (HEK293-
ABCG2, also called “293BCRP3, CelluloNet n° 234”) or the empty vector (HEK293-
pcDNA3) or ABCG2 mutants. Stable polyclonal cell lines were then selected with 
0.75mg/ml G418, and cell lines were cloned. They were maintained in high-glucose 
DMEM supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin 
at 37 °C, 5% CO2 under controlled humidity. The cell culture medium was 
supplemented with 0.75 mg/mL G418.  
 
5D3 binding 
In studies with the anti-ABCG2 antibody 5D3, cells were incubated in 2% BSA/DPBS 
(Dulbecco’s Phosphate Buffered Saline) with either phycoerythrin-labeled negative 
control antibody (IgG2b) or phycoerythrin-labeled 5D3 antibody (both from 
eBioscience, San Diego, CA), used in excess according to the manufacturer’s 
instructions, washed with DPBS, and subsequently analyzed. Surface expression of 
ABCG2 was calculated as the difference in mean channel numbers between the 5D3 
histogram and the negative-control antibody histogram. Samples were analyzed on a 
FACSort flow cytometer (Becton Dickinson, San Jose, CA). Phycoerythrin 
fluorescence was detected with a 488 nm argon laser and a 585 nm bandpass filter. 
At least 10,000 events were collected for each flow cytometry experiment. By gating 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
7 
 
on forward versus side scatter, debris was eliminated, and dead cells were excluded 
based on propidium iodide staining. 
 
Mitoxantrone efflux and inhibition by characteristic inhibitors 
HEK-293 cells expressing wild-type or mutated ABCG2 were trypsinized and 
incubated for 30 min with 20 µM mitoxantrone in the presence or absence of 10 µM 
of the ABCG2 inhibitor fumitremorgin C (FTC). Cells were then washed and 
incubated for 1 h in mitoxantrone-free medium continuing with or without FTC. 
Mitoxantrone efflux was calculated by subtracting the mean fluorescence of the cells 
incubated without FTC from the mean fluorescence of the cells incubated with FTC 
as previously described [28]. 
 
Cell growth resistance to mitoxantrone 
HEK-293 cells expressing wild-type or mutated ABCG2, as well as control cells were 
seeded at a density of 104 cells/well into 96-well culture plates, incubated overnight, 
and treated with mitoxantrone (up to 1 M) for 72 h. To assess viability, the cells 
were exposed to 0.5 mg/mL MTT and incubated for 4 h at 37 C [29]. The culture 
medium was discarded, and 100 L of a DMSO/ethanol (1:1) solution was added into 
each well and mixed by gently shaking for 10 min. Absorbance was measured at 570 
nm using a microplate reader, and the value measured at 690 nm was subtracted. 
Data are the mean ± SD of at least three independent experiments. 
  
ATPase activity assay 
Beryllium-fluoride-sensitive ATPase activity was assayed using crude membranes 
(10 µg protein/tube) of HEK293 cells expressing WT and mutant ABCG2 as 
described previously [30]. Briefly crude membranes isolated from HEK cells 
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expressing ABCG2 (1 mg of protein/ml) were incubated at 37°C in ATPase assay 
buffer (50 mM KCl, 5 mM sodium azide, 2 mM EGTA, 1 mM ouabain, 10 mM MgCl2, 
2 mM dithiothreitol, and 50 mM Tris-MES, pH 6.8)  in the presence or absence of 
indicated substrates for 5 min. The ATPase reaction was started by the addition of 5 
mM ATP and was terminated by the addition of 0.1 ml SDS solution after 20 min. The 
amount of inorganic phosphate released was quantified by a colorimetric reaction as 
described previously [30]. 
 
Results 
Identification of a specific C2-sequence in human ABCG2 
Sequence alignment of the different human ABCG transporters indicated the 
following consensus for the canonical ABC signature/C-motif, L/V-S-G-G-E/Q 
followed by R-K/R-R (Fig. 1A), except for some degenerescence in ABCG5 which is 
fuctionally active as an heterodimer with ABCG8. The ABCG2 sequence located at 
positions 188-192 was V-S-G-G-E. Quite interestingly, a very similar additional 
sequence, called hereafter C2-sequence (L-S-G-G-E, followed by K-K-K), was found 
exclusively in human ABCG2, at positions 352-356 (Fig. 1B). It obeyed the 
consensus sequence illustrated here above for human ABCG members, and known 
to be common to all ABC transporters; it could therefore be defined as an extra, non-
canonical, C-motif. Sequence alignment of human ABCG2 with ABCG2 homologues 
from different species indicated in Fig. 1C that this non-canonical human C2-
sequence was well conserved in mammals (elephant, dog, horses, goat, bovines, 
ovines, primates and rodents), partly in avian organisms (chicken, turkey) and in 
amphibia, but not in fishes, protozoan parasites and plants. Interestingly, no C2-
sequence was found in yeast MDR full-transporters, with similar domain organisation 
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as ABCG2, such as Saccharomyces cerevisiae Pdr5p or Candida albicans Cdr1p 
(not shown). 
 Secondary structure predictions indicate the C2-sequence located at the 
border of an -helix and a region without stable secondary structure similarly as the 
canonical C-motif. Moreover, the latter segment around a.a. 360 is predicted to be 
the most disordered part of the 301-396 linker region when using the DISPORED2 
program, and one among the regions with higher disorder tendency determined by 
the IUPred program (Fig. 2). The coherence of the secondary structure and disorder 
predictions employing different algorithms strengthens the hypothesis that the C2-
sequence can be embedded into a similar structural environment as the canonical C-
motif. 
 
Slight alterations of C2-sequence mutations on cell surface expression and activity of 
ABCG2  
Single point mutation into alanine of each of the five residues of the C2-sequence 
(L352-S353-G354-G355-E356) induced variable consequences on the total ABCG2 
expression monitored by Western blotting with the BXP-21 ABCG2-specific antibody: 
from at least 2-fold decrease versus the wild-type protein for L352A, S353A and 
E356A mutants, to no apparent effect for the G354A and G355A mutants (not shown 
here). However, the plasma membrane expression of ABCG2, as monitored with the 
5D3 antibody recognizing the ABCG2 extracellular loop 3, was hardly modified 
except for the S353A mutant exhibiting a decrease of 13% (Fig. 3A-B). The correct 
trafficking to plasma membrane was visualized and confirmed by confocal 
microscopy (Fig. 3C). Mitoxantrone efflux was measured by flow cytometry as 
differential intracellular accumulation (Fig. 4A-B) and was also corrected for the small 
differences observed in membrane expression: the two L352A and S353A mutants 
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showed a moderate decrease of 23-32% in activity when compared to that of the 
wild-type ABCG2 (Fig. 4C). Symmetrically, a positive control with the gain-of-function 
R482G mutant showed a marked increase in mitoxantrone efflux: about 45% versus 
wild-type ABCG2, and 90-115% versus the two L352A and S353A mutants. 
 
C2-mutants exhibit a markedly decreased resistance to mitoxantrone 
The consequences of point mutations were much more pronounced in 72 h long 
cytotoxicity assays, performed in the presence of mitoxantrone and quantified by a 
cell survival MTT test. A complete loss of resistance to mitoxantrone cytotoxicity was 
observed with both L352A (Fig. 5A) and S353A (Fig. 5B) mutants, both of which 
reached sensitivity levels similar to that of the ABCG2-negative HEK-293 control cells 
transfected with the empty pcDNA3.1 vector. A lower, but significant, 
chemosensitization was observed with the G354A (Fig. 5C) and E356A (Fig. 5D) 
mutants. 
 
Alterations of basal and drug-stimulated ATPase activities 
The beryllium-fluoride-sensitive ATPase activity of membranes, prepared from 
resistant ABCG2-overexpressing HEK-293 cells, was altered upon point mutations, 
both in the absence or presence of drug substrate (Fig. 6). While the basal ATP 
hydrolysis (14.6 nmol Pi/min.mg protein) was decreased (up to 30%) for the S353A 
mutant, L352A and S353A mutants showed at least a 3-fold decrease in the Km 
values for ATP hydrolysis (Fig. 6A). More strikingly, the stimulation of basal ATPase 
activity in the wild-type protein by transport substrates such as nilotinib [31] was 
completely abolished in L352A and S353A mutants (Fig. 6B), whereas nilotinib still 
stimulated the ATPase activity of G354A and E356A mutants. 
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Alterations of the interaction with different types of drug-efflux inhibitors 
The point-mutation effect on the efficiency of different types of inhibitors was studied 
with S353A, the most altered mutant, in comparison with wild-type ABCG2 (Fig. 7). 
The inhibition of mitoxantrone efflux by Ko143, an ABCG2-selective and highly-
potent inhibitor [32] known to also inhibit the basal ATPase activity [33] and not to be 
transported, was found here to be strongly impaired in this mutant. The EC50 of  
Ko143 [34) and chromone 1 [27], which are known to inhibit ABCG2-mediated 
mitoxantrone efflux, was increased from 0.06 to 0.26 µM (4.3-fold increase) and from 
0.11 to 0.39 µM (3.5-fold increase), respectively (Fig. 7A and 7B). By contrast, no 
significant alteration in the EC50 values was observed for the inhibition of activity by 
nilotinib, a competitive inhibitor [35] known to be transported by ABCG2 [31] (Fig. 
7C). 
 
Discussion 
This paper demonstrates the functional role of a selective sequence of human 
ABCG2, identified as a potential extra ATP-binding motif, and its unique implication in 
the coupling mechanism between ATP hydrolysis and drug-efflux activity.  
 
The ABCG2-selective C2-sequence as an additional C-motif? 
Three different approaches have identified the C2-sequence LSGGE, at 352-356 
positions of human ABCG2, as a possible nucleotide-binding motif. First, sequence 
alignment unambiguously showed complete agreement with the consensus 
sequence of the canonical C-motif/ABC signature found in all NBDs; second, 
disorder and secondary-structure predictions indicate the C2-sequence to be located 
between an -helix and a loop similarly to the canonical C-motif; third, the strong 
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alterations induced upon point-mutations further confirmed a critical function, 
associated to both ATPase and drug-efflux activities. 
 This suggests that the C2-sequence, belonging to the linker connecting NBD 
and TMD, might be possibly located close to the ATP-binding site of the NBD to 
directly interact with bound nucleotide. The C2-sequence, at positions 352-356, is 
distant by about 40 residues from the beginning of TMD, which is similar to the length 
of the intracellular loops in crystallized bacterial Sav1866 [12] and eukaryotic 
P-glycoproteins [10, 11]. However, it not known if the presence of the C2-sequence 
might compensate the lack of a long intracellular loop, as shown in the human 
ABCG2 molecular model [36], or if such a multidrug homodimeric half-transporter 
might require additional interactions than full-transporters such as ABCB1 and 
ABCC1. It is not either known if the absence of such a C2-sequence in lower 
eukaryotes might be correlated to differences in the regulation of activity or in 
structural divergence of these ABCG2 homologs.  
 
A critical function of the C2-sequence  
Single-point mutations have allowed here the identification of two types of dramatic 
functional alterations. The first type concerned the ATPase activity, for which a 
decrease in both Vmax and Km for ATP hydrolysis was observed; this suggested a role 
of the C2-sequence in either ATP binding or in ADP release, which is known to be 
often a rate-limiting step of ATP hydrolysis for various ATPases. In addition, the 
complete abolition of drug-induced stimulated ATP hydrolysis, recognized as 
coupling ATPase activity, was consistent with the strong catalytic impairment 
observed upon C-motif point-mutations in various ABC transporters, such as the 
second glycine in either only P-glycoprotein NBD1 [13] or both MRP1 NBD1 and 
NBD2 [15], the two serines in both P-glycoprotein NBD1 and NBD2 [14], and either 
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single glycine or glutamine in homodimeric MalK [18]. For TAP1/TAP2 heterodimer, it 
was demonstrated, by point-mutations within both monomers and C-motifs exchange 
in chimeras, that the strong alterations observed on substrate transport were 
correlated to changes in ATP hydrolysis [17], and not to ATP binding [16], and that 
the natural substitutions in degenerated TAP2 (AA versus SG in canonical TAP1) 
allowed the control of transport activity and coupled ATP hydrolysis [17]. It is not 
known whether residues of the ABCG2 C2-sequence might additionally establish 
protein-protein interactions contributing to the closure/dimerization of NBDs as shown 
for the C-motif within the crystal structure of HlyB [19]. The much stronger 
consequences induced on coupled versus basal ATPase indicates that both activities 
obey distinct mechanisms, as previously concluded from different approaches with 
either ABCG2 [34] or P-glycoprotein [37].  
The second type of alteration concerned drug-efflux activity: i) the complete 
loss of cellular resistance to mitoxantrone cytotoxicity, upon 3-day culturing, 
appeared to contrast with the only partial decrease of mitoxantrone efflux observed in 
short-term flow-cytometry experiments. Different hypothetical explanations might be 
considered, such as time-dependent amplification under cell-culture conditions of the 
initially moderate alteration of drug efflux, changed IC50 values of mitoxantrone for its 
target, or mitoxantrone-induced lowered metabolic activity of mutant cells reducing 
ATP concentration below treshold for basal ATPase activity (?). A marked alteration 
in substrate transport was also observed upon TAP1/TAP2 mutations, as mentioned 
above [16, 17]. Since the same C2-sequence point mutations induced a complete, 
primary, alteration of coupled ATP hydrolysis, the alterations observed on drug efflux 
might be considered as consequences, or secondary effects, rather than a direct 
contribution of mutated residues; ii) the strong alteration of the potent, selective, and 
noncompetitive Ko143 and chromone 1 inhibitors [34], known to inhibit basal ATPase 
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activity, suggested (despite their high hydrophobicity) a rather “cytosolic” inhibitor-
binding site, in close proximity to the NBDs where ATP binds, although a distant 
conformational change cannot be excluded. The interaction of these inhibitors with 
the selective C2-sequence might, at least partly, explain their ABCG2 selectivity 
versus the other multidrug ABC transporters P-glycoprotein/ABCB1 and 
MRP1/ABCC1. 
It may be concluded that the C2-sequence, especially L352 and S353 in human 
ABCG2, plays a unique role in coupling ATP hydrolysis to drug efflux, and related 
conformational changes of the transporter. This might constitute a new selective 
target to antagonize multidrug resistance in ABCG2-overexpressing cancer cells. 
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Figure captions 
Fig. 1. Sequence alignment of human ABCG sub-family members, emphasizing the 
regions containing the canonical signature/C-motif (marked with a blue line) (A) or a 
non-canonical C2-sequence that is only present in ABCG2 (marked with red line) (B). 
Alignment of the linker region containing the non-canonical C2-sequence of human 
ABCG2 with homologous regions of ABCG2 homologs from various species (C). 
 
Fig. 2. Predictions of disorder within the linker region of human ABCG2 containing 
the LSGGE C2-sequence at positions 352-356. The arrows show the C2-sequence 
position. 
 
Fig. 3. Detection and quantification of the C2-sequence point mutants within the 
plasma membrane of transfected cells by flow cytometry with the 5D3 surface 
antibody. Stably-transfected HEK293 cells were incubated with phycoerythrin-labeled 
5D3 antibody (blue line) or a negative control antibody (red line) (A). Similarly to wild-
type ABCG2, the C2-sequence mutants and the R482G gain-of-function mutant were 
detected on the cell surface, and quantified by 5D3 fluorescence; the bars represent 
the mean of median fluorescence (B). HEK293 cells with stable expression of either 
pcDNA3.1 empty vector, wild-type ABCG2 or the C2-sequence L352A mutant were 
ﬁxed and immunostained with the ABCG2-specific BXP-21 antibody, and nuclei were 
counterstained with 4’,6-diamidino-2-phenylindole (DAPI) (C) .  
 
Fig. 4. Mutation-induced alterations of ABCG2-mediated drug-efflux activity. HEK293 
cells expressing wild-type ABCG2, the different C2-sequence mutants or the R482G 
gain-of-function mutant were incubated with 20 µM mitoxantrone with (blue line) or 
without (red line) 10 µM fumitremorgin C (FTC) as a specific inhibitor, to generate the 
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histograms (A). The efflux was quantified by difference between the two histograms 
either without further corrections (B) or by taking into account the exact plasma 
membrane ABCG2 content determined in Fig. 3B (C).    
 
Fig. 5. Mutation-induced sensitization to mitoxantrone toxicity of the growth of 
multidrug-resistant cells. The different sensitivities to mitoxantrone of transfected 
HEK293 cells with stable expression of wild-type ABCG2 (in green) or the control 
pcDNA3.1 empty vector (in magenta) were compared to that of ABCG2 mutants (in 
black) with the following point mutations: L352A (A), S353A (B), G354A  (C) or 
E356A (D). The cells were cultured on monolayer at day 0, and increasing 
concentrations of mitoxantrone were added to cells at day 1 until day 5; they were 
stained with MTT, and the absorbance read at 570 nm. Data points represent mean 
values ± SD (n = 3). 
 
Fig. 6. Differential mutation-induced alterations of basal (A) and substrate-stimulated 
(B) ATPase activity of ABCG2. (A) Crude membranes from transfected HEK293 cells 
expressing wild-type ABCG2, or the L352A, S353A or E356A mutant were incubated 
in the presence or absence of beryllium-fluoride (0.2 mM beryllium sulfate and 2.5 
mM sodium fluoride) in ATPase assay buffer with increasing ATP concentrations in 
the absence of substrate drug. (B) The drug-stimulated activity was measured at 5 
mM ATP upon addition of 0.25 µM nilotinib (grey bars) in comparison to the basal 
activity without substrate addition (black bars). The results are expressed as mean 
values ± standard deviations from three independent experiments. 
 
Fig. 7. Mutation-induced alterations of ABCG2 interaction with different types of 
inhibitors. The efflux of mitoxantrone by HEK293 cells expressing either wild-type 
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ABCG2 (circles) or the S353A mutant (triangles) was measured by flow cytometry as 
in Fig. 4. Its inhibition by increasing concentrations of Ko143 (A), chromone 1 (B) or 
nilotinib (C) was plotted as indicated. 
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